

Cover Story
																				By Matthew Bin Han Ong
Moving away from recommendations dating back to 2009, the U.S. Preventive Services Task Force now states that women should start biennial screening for breast cancer at age 40—instead of 50—a change that experts say is based on new, inclusive science.
In Brief
Clinical Roundup


Drugs & Targets
Trending Stories
- Class action complaint alleging GRAIL insider fraud resubmitted after dismissal
 - Cancer centers adapt to life without site visits as NIH changes CCSG review
 - GRAIL to use new study results to seek FDA approval of Galleri MCD test
 - Jonathan Licht named president, chief scientific officer at Van Andel Institute
 - Friends publishes three white papers ahead of annual meeting
Topics: Clinical trials on rare cancers, combination drug trials, multi-regional studies - Duke brain cancer researcher Kyle Walsh named director of NIEHS
 
            
















